Solutions Manual _ Answers for Karch's Focus on Nursing Pharmacology, 9th Edition by Tucker (All Chapters included)

SOLUTIONS MANUAL




** All Chapters included
** Answers to discussion topics
** Answers to assignments
** Answers to case studies
** Guided lecture notes

,Table of Contents are given below
Chapter 1. Introduction to Drugs
Chapter 2. Drugs and the Body
Chapter 3. Toxic Effects of Drugs
Chapter 4. The Nursing Process in Drug Therapy and Patient Safety
Chapter 5. Dosage Calculations
Chapter 6. Challenges to Effective Drug Therapy
Chapter 7. Introduction to Cell Physiology
Chapter 8. Antiinfective Agents
Chapter 9. Antibiotics
Chapter 10. Antiviral Agents
Chapter 11. Antifungal Agents
Chapter 12. Antiprotozoal Agents
Chapter 13. Anthelmintic Agents
Chapter 14. Antineoplastic Agents
Chapter 15. Introduction to the Immune Response and Inflammation
Chapter 16. Antiinflammatory, Antiarthritis, and Related Agents
Chapter 17. Immune Modulators
Chapter 18. Vaccines and Sera
Chapter 19. Introduction to Nerves and the Nervous System
Chapter 20. Anxiolytic and Hypnotic Agents
Chapter 21. Antidepressant Agents
Chapter 22. Psychotherapeutic Agents
Chapter 23. Antiseizure Agents
Chapter 24. Antiparkinsonism Agents
Chapter 25. Muscle Relaxants
Chapter 26. Opioid Agonists, Opioid Antagonists, and Antimigraine Agents
Chapter 27. General and Local Anesthetic Agents
Chapter 28. Neuromuscular Junction Blocking Agents
Chapter 29. Introduction to the Autonomic Nervous System
Chapter 30. Adrenergic Agonists
Chapter 31. Adrenergic Antagonists
Chapter 32. Cholinergic Agonists
Chapter 33. Anticholinergic Agents
Chapter 34. Introduction to the Endocrine System
Chapter 35. Hypothalamic and Pituitary Agents
Chapter 36. Adrenocortical Agents
Chapter 37. Thyroid and Parathyroid Agents
Chapter 38. Agents to Control Blood Glucose Levels
Chapter 39. Introduction to the Reproductive System
Chapter 40. Drugs Affecting the Female Reproductive System
Chapter 41. Drugs Affecting the Male Reproductive System
Chapter 42. Introduction to the Cardiovascular System
Chapter 43. Drugs Affecting Blood Pressure
Chapter 44. Agents for Treating Heart Failure
Chapter 45. Antiarrhythmic Agents
Chapter 46. Antianginal Agents
Chapter 47. Lipid-Lowering Agents
Chapter 48. Drugs Affecting Blood Coagulation
Chapter 49. Drugs Used to Treat Anemias
Chapter 50. Introduction to the Renal System
Chapter 51. Diuretic Agents
Chapter 52. Drugs Affecting the Urinary Tract and the Bladder
Chapter 53. Introduction to the Respiratory System
Chapter 54. Drugs Acting on the Upper Respiratory Tract
Chapter 55. Drugs Acting on the Lower Respiratory Tract
Chapter 56. Introduction to the Gastrointestinal System
Chapter 57. Drugs Affecting Gastrointestinal Secretions
Chapter 58. Drugs Affecting Gastrointestinal Motility
Chapter 59. Antiemetic Agents
Chapter 60. Vitamin, Minerals, and Complementary/Alternative Medications

,Suggested Answers to Discussion Topics, Chapter 1,
Introduction to Drugs

Suggested Answers to Discussion Topics Learning
Objective(s)
1a. Students’ answers should include the following: 2
 In a phase II study, the drug is evaluated in patients
who have the disease the drug is designed to treat. A
drug may be removed from further investigation after
phase II studies because it is less effective than
anticipated, is too toxic, produces unacceptable adverse
effects, has a low benefit-to-risk ratio, or is no more
effective than other drugs already on the market.
Because these aspects have not been established at this
point, there are risks to participants. For this reason, it is
important that participants are fully informed about
possible risks before consenting to participate.


1b. Students’ answers should include the following:
 The Food and Drug Administration (FDA) is an
agency of the U.S. Department of Health and Human
Services that regulates the development and sale of
drugs. FDA-regulated tests are designed to ensure the
safety and reliability of any drug approved in this
country. Before receiving final FDA approval to be
marketed to the public, drugs must pass through
preclinical trials and phase I, II, and III studies. The FDA
is involved in each stage of evaluation.
2. Students’ answers should include the following: 5
 Brand name: name given to the drug by the
manufacturer
 Generic name: chemical name of the drug listed in the

, Suggested Answers to Discussion Topics Learning
Objective(s)
National Formulary
 Drug dose: dose available in this product
 Administration: some labels indicate route and dosage
 Lot number: specific drug batch from which the drug was
produced; important for recall information
 Expiration date: the date after which the drug should no
longer be used
 Warnings: specific drug warnings
 Quantity: amount of the drug in the package
 Drug manufacturer: pharmaceutical house that produces
the drug
 Storage information
3a. Students’ answers should include the following: 3
 Each prescriber has a DEA number, which allows the DEA
to monitor prescription patterns and possible abuse.
 Local policies and procedures, including narcotic record
administration and drug count records, may be even
more rigorous.


3b. Students’ answers should include the following:
DEA-controlled substance categories indicate the abuse
potential and associated regulation of a drug. The categories
are as follows:
 Schedule I (C-I): High abuse potential and no accepted
medical use (heroin, LSD)
 Schedule II (C-II): High abuse potential with severe
dependence liability (narcotics, amphetamines, and
barbiturates)
 Schedule III (C-III): Less abuse potential than
schedule II drugs and moderate dependence liability